Corient Private Wealth LP Invests $1.22 Million in Tango Therapeutics, Inc. $TNGX

Posted by Brenda Bartman on Sep 5th, 2026

Corient Private Wealth LP acquired a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 39,024 shares of the company’s stock, valued at approximately $1,220,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TNGX. Allworth Financial LP purchased a new stake in Tango Therapeutics during the 2nd quarter worth about $35,000. Global Retirement Partners LLC purchased a new position in shares of Tango Therapeutics in the 2nd quarter valued at about $122,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Tango Therapeutics in the 4th quarter valued at about $40,000. State of Wyoming acquired a new position in shares of Tango Therapeutics during the first quarter worth about $128,000. Finally, Legal & General Group Plc grew its position in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after buying an additional 1,640 shares in the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Tango Therapeutics Price Performance

Shares of NASDAQ:TNGX opened at $22.52 on Friday. The company’s fifty day moving average price is $27.05 and its 200 day moving average price is $23.48. Tango Therapeutics, Inc. has a 12 month low of $6.25 and a 12 month high of $34.39. The firm has a market capitalization of $3.80 billion, a P/E ratio of -26.49 and a beta of 1.12.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). On average, sell-side analysts anticipate that Tango Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Buying and Selling at Tango Therapeutics

In other news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the sale, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. The trade was a 18.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on TNGX. Guggenheim raised their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Raymond James Financial downgraded shares of Tango Therapeutics to a “hold” rating in a research report on Thursday, June 25th. HC Wainwright raised their price objective on shares of Tango Therapeutics from $66.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Wolfe Research set a $35.00 target price on shares of Tango Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 8th. Finally, Wall Street Zen cut Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tango Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $43.46.

View Our Latest Research Report on Tango Therapeutics

Tango Therapeutics Company Profile

(Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.